<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368340</url>
  </required_header>
  <id_info>
    <org_study_id>150104</org_study_id>
    <secondary_id>U54HL127672</secondary_id>
    <nct_id>NCT02368340</nct_id>
  </id_info>
  <brief_title>A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis</brief_title>
  <official_title>A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hermansky-Pudlak Syndrome (HPS) is a rare genetic disease that is associated with
      oculocutaneous albinism, bleeding, granulomatous colitis, and pulmonary fibrosis in some
      subtypes, including HPS-1, HPS-2, and HPS-4. Pulmonary fibrosis causes shortness of breath
      and progressive decline in lung function. In HPS patients with at-risk subtypes, almost all
      adults eventually develop fatal pulmonary fibrosis unless they undergo lung transplantation.

      The purpose of this study is to identify the earliest measurable pulmonary disease activity
      in individuals at-risk for HPS pulmonary fibrosis. The study also aims to develop biomarkers
      that will aid in understanding of the causes of HPS pulmonary fibrosis and facilitate more
      rapid conduct of therapeutic trials in HPS patients with mild pulmonary disease in the
      future.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Chest CT scan</measure>
    <time_frame>change in CT Scan from baseline to 2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function test</measure>
    <time_frame>change in PFTs from baseline to 2.5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hermansky Pudlak Syndrome</condition>
  <arm_group>
    <arm_group_label>Adults with pulmonary fibrosis</arm_group_label>
    <description>This group includes adults with HPS who have known pulmonary fibrosis. Subjects in this group will provide blood and urine specimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults at-risk</arm_group_label>
    <description>This group includes adults with HPS with subtypes at-risk for pulmonary fibrosis, but who do not have known pulmonary fibrosis.
Subjects in this group will undergo chest CT and pulmonary function testing, and provide blood and urine specimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HPS adults not at-risk</arm_group_label>
    <description>This group includes adults with HPS subtypes considered not at-risk for pulmonary fibrosis.
Subjects in this group will provide blood and urine specimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children with HPS at-risk</arm_group_label>
    <description>This group includes children with HPS subtypes at-risk for pulmonary fibrosis. Subjects in this group will undergo pulmonary function testing, and provide blood and urine specimens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pulmonary function test</intervention_name>
    <description>Pulmonary function testing performed</description>
    <arm_group_label>Adults at-risk</arm_group_label>
    <arm_group_label>Children with HPS at-risk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chest CT</intervention_name>
    <description>Chest CT scan to evaluate for pulmonary fibrosis</description>
    <arm_group_label>Adults at-risk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sample collection</intervention_name>
    <description>Blood and urine sample collections</description>
    <arm_group_label>Adults with pulmonary fibrosis</arm_group_label>
    <arm_group_label>Adults at-risk</arm_group_label>
    <arm_group_label>HPS adults not at-risk</arm_group_label>
    <arm_group_label>Children with HPS at-risk</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine, lymphocytes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with diagnosis of Hermansky-Pudlak Syndrome
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals ages 12-90 years with confirmed diagnosis of HPS as defined by
             verification of reduced or absent platelet dense granules by electron microscopy
             and/or genetic diagnosis

          -  Ability to provide informed consent, or consent of parent/guardian and assent for
             minors

        Exclusion Criteria:

          -  Status-post lung transplantation

          -  Perceived unsuitability for participation in the study in the opinion of the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa R. Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa R. Young, MD</last_name>
    <phone>615-343-7617</phone>
    <email>Lisa.Young@vanderbilt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Errine Garnett</last_name>
    <phone>615-343-0539</phone>
    <email>errine.t.garnett@vanderbilt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic - Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Burger, MD</last_name>
      <phone>904-953-2282</phone>
      <email>burger.charles@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Dilling, MD</last_name>
      <phone>708-216-0461</phone>
      <email>ddillin@lumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital, Harvard</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Souheil El-Chemaly, MD</last_name>
      <phone>617-732-6869</phone>
      <email>Sel-chemaly@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Lederer, MD</last_name>
      <phone>212-305-6589</phone>
      <email>dl427@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Trapnell, MD</last_name>
      <phone>513-636-6361</phone>
      <email>bruce.trapnell@cchmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa R. Young, MD</last_name>
      <phone>615-343-7617</phone>
      <email>Lisa.Young@vanderbilt.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Lisa Young</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Hermanski-Pudlak Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

